Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 5/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | RARB | P10826 | 3/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8640999 | 1.00 | PLA2G2A (0.64) | PLA2G2ATP53TSHRPLA2G4BBLM | |
| SCHEMBL5104447 | 0.93 | PLA2G2A (0.54) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL8648767 | 0.82 | PLA2G2A (0.66) | PLA2G2ATP53TSHRPLA2G4BBLM | |
| SCHEMBL2799007 | 0.81 | PTGS2 (0.44) | PLA2G2ATP53TSHRPLA2G4B | |
| SCHEMBL20556375 | 0.81 | THRB (0.64) | PLA2G2ATP53TSHRPLA2G4BBLM | |
| SCHEMBL9626748 | 0.80 | RARB (0.66) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL7814595 | 0.80 | RARB (0.66) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL9407183 | 0.80 | PTPN1 (0.48) | PLA2G2ATP53TSHRPLA2G4BTHRB | |
| SCHEMBL7824715 | 0.80 | RARB (0.66) | PLA2G2ATP53TSHRPLA2G4BRARB | |
| SCHEMBL1583118 | 0.80 | RARB (0.66) | PLA2G2ATP53TSHRPLA2G4BRARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9059410-B2 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2015-06-16 | — | — | US | disclosed |
| US-9059410-B2 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2015-06-16 | — | — | US | disclosed |
| EP-1894984-B1 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | NAT INST OF ADVANCED IND SCIEN (JP) | 2011-04-20 | — | — | EP | disclosed |
| US-20080058544-A1 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-03-06 | — | — | US | disclosed |
| US-20080058544-A1 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1894984-A1 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | National Institute of Advanced Industrial Science and Technology (JP) | 2008-03-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058544-A1 | Liquid crystalline organic semiconductor material and organic semiconductor device using same | SLCO4C1, SLCO2A1, SLCO1A2 | PLA2G2A 3969/4885TP53 1487/4885TSHR 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.